Drug Trial Radar · NCT06146101
RePOSA-Revealing the Efficacy of IHL-42X Use in Patients With OSA
Last checked: Nov 20, 2026Latest source record: Jul 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
121
Actual
Start
May 2, 2024
Primary completion
May 20, 2025
Study completion Jul 27, 2025
Sponsor
- Lead sponsor
- Incannex Healthcare LtdIndustry
- Sponsor type
- Industry
- First posted
- Nov 24, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this randomised, double-blind phase II/III clinical trial is to determine the safety and efficacy of IHL-42X in subjects with obstructive sleep apnoea who are intolerant, non-compliant, or naïve to positive airway pressure. Phase II study will be a 4-week dose-finding study comparing two dose strengths of IHL-42X to placebo. The optimal dose strength will be selected based on comparing the safety and efficacy of the two IHL-42X dose strengths to placebo over a 4-week treatment period. The three treatment groups are; IHL-42X Low dose (2.5mg dronabinol, 125mg acetazolamide), IHL-42X High dose (5mg dronabinol, 250mg acetazolamide) and Placebo. Each treatment group will enrol approximately 40 patients per treatment arm, for a total of approximately 120 patients. The safety and efficacy results of the Phase II study will be used to select the dose strength of IHL-42X and corresponding doses of dronabinol and acetazolamide in Phase III. Phase III study will use the optimal dose strength of IHL-42X identified in Phase II and will be compared to the component active pharmaceutical ingredients at equivalent dose strengths to those found in the IHL-42X optimal dose strength and placebo over 52 weeks. The four treatment groups are; IHL-42X (optimal dose from Phase II), Acetazolamide (equivalent dose strength to that in the IHL-42X optimal dose strength), Dronabinol (equivalent dose strength to that in the IHL-42X optimal dose strength) and placebo. The treatment groups will enrol approximately 165 patients in IHL-42X, approximately 55 patients in dronabinol, approximately 55 in acetazolamide, and approximately 165 in placebo, for a total of approximately 440 patients.
Conditions
- Obstructive Sleep Apnea
Interventions
IHL-42X Low DoseDrug
Softgel capsule
IHL-42X High DoseDrug
Softgel capsule
PlaceboDrug
Softgel capsule
IHL-42X (Optimal Dose)Drug
Softgel capsule
DronabinolDrug
Softgel capsule
AcetazolamideDrug
Softgel capsule
PlaceboDrug
Softgel capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in apnea-hypopnea index (AHI)Time frame: 4 weeks
- Change in apnea-hypopnea index (AHI)Time frame: 52 weeks
Locations
20 sites in 1 country. Site status is shown where the registry gives one.
Exalt Clinical Research
Chula Vista, California
CenExel CNS- Los Alamitos
Long Beach, California
Pacific Clinical Research Medical Group
Upland, California
Clinical Neuroscience Solutions, Inc. (CNS Healthcare of Jacksonville)
Jacksonville, Florida
Clinical Neuroscience Solutions, Inc. (CNS Healthcare of Orlando)
Orlando, Florida
Teradan Clinical Trials
Valrico, Florida
Palm Beach Research Center
West Palm Beach, Florida
NeuroTrials Research, Inc.
Atlanta, Georgia
Tandem Clinical Research, LLC
Marrero, Louisiana
Centennial Medical Group
Elkridge, Maryland
Meridian Clinical Research, LLC
Rockville, Maryland
Henderson Clinical Trials,LLC
Henderson, Nevada
Advanced Respiratory and Sleep Medicine, PLLC
Huntersville, North Carolina
CTI Clinical Trial and Consulting Services
Cincinnati, Ohio
Intrepid Research
Cincinnati, Ohio
Velocity Clinical Research - Anderson
Anderson, South Carolina
Velocity Clinical Research - Greenville
Greenville, South Carolina
Clinical Neuroscience Solutions, Inc. (CNS Healthcare of Memphis)
Memphis, Tennessee
FutureSearch Trials
Austin, Texas
FutureSearch Trials of Dallas, LP
Dallas, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.